Future opportunity

NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins

  • NHS England

F01: Prior information notice (prior information only)

Notice reference: 2024/S 000-008035

Published 13 March 2024, 1:47pm



Section one: Contracting authority

one.1) Name and addresses

NHS England

1st Floor, Quarry House, Quarry Hill

Leeds

LS2 7UE

Contact

Jennifer Tierney

Email

Jennifer.Tierney@england.nhs.uk

Country

United Kingdom

NUTS code

UKE - Yorkshire and the Humber

Internet address(es)

Main address

https://www.england.nhs.uk//

Buyer's address

https://www.england.nhs.uk//

one.3) Communication

Additional information can be obtained from the above-mentioned address

Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at

https://health-family.force.com/s/Welcome

one.4) Type of the contracting authority

Ministry or any other national or federal authority

one.5) Main activity

Health


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins

Reference number

CM/PHS/23/5703

two.1.2) Main CPV code

  • 33651520 - Immunoglobulins

two.1.3) Type of contract

Supplies

two.1.4) Short description

This market engagement relates to the NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins. The framework is anticipated to commence on 1 January 2025 for a period of 36 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. Total maximum framework agreement including extension options will be no more than 48 months. The purpose of the PIN is to engage with the supply market on the procurement approach and to understand market and supplier capacities prior to the Invitation to Tender.

two.1.5) Estimated total value

Value excluding VAT: £1,400,000,000

two.1.6) Information about lots

This contract is divided into lots: Yes

two.2) Description

two.2.1) Title

1-7

Lot No

1-7

two.2.2) Additional CPV code(s)

  • 33651520 - Immunoglobulins

two.2.3) Place of performance

NUTS codes
  • UK - United Kingdom
Main site or place of performance

Framework intended for use by the NHS in England, Northern Ireland, Scotland. The agreement may also be used by private sector contractors and agents working on behalf of the above.

two.2.4) Description of the procurement

This market engagement relates to the NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins. The framework is anticipated to commence on 1 January 2025 for a period of 36 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. Total maximum framework agreement including extension options will be no more than 48 months. The purpose of the PIN is to engage with the supply market on the procurement approach and to understand market and supplier capacities prior to the Invitation to Tender.

two.3) Estimated date of publication of contract notice

28 May 2024


Section four. Procedure

four.1) Description

four.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes


Section six. Complementary information

six.3) Additional information

This market engagement relates to the NHS Framework Agreement for the supply of licenced Human Albumin Solution & Normal and Anti-D Immunoglobulins. The framework is anticipated to commence on 1 January 2025 for a period of 36 months, with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. Total maximum framework agreement including extension options will be no more than 48 months.

The purpose of the PIN is to engage with the supply market on the procurement approach and to understand market and supplier capacities prior to the Invitation to Tender.

The market engagement documents will be made available during March for unrestricted and full direct access, free of charge, at http://health.atamis.co.uk under project reference C228466.

Please be aware the NHSE principal address has changed to Wellington House 133-155 Waterloo Road London SE1 8UG